GlassScriptPhysician profile
Haley Ammons Perry
NPI 1629302005
$79,332.83
in general payments reported to CMS, 2019-2025
23 companies · $68K in 2025
The $68K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,752 · 2020: $361 · 2021: $583 · 2022: $820 · 2023: $1,101 · 2024: $5,608 · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,500 · Travel and Lodging: $1,549 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Entertainment: $92.72 · Education: $11.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70,164.58 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,500.00 |
| Travel and Lodging | $1,548.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Entertainment | $92.72 |
| Education | $11.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $66,605.04 | 2022-2025 | Optilight, M22 |
| Sun Pharmaceutical Industries INC. | $4,109.21 | 2019-2025 | Cequa |
| Coopervision INC. | $2,597.64 | 2019-2025 | Cvi Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,362.62 | 2019-2021 | |
| Alcon Vision LLC | $739.41 | 2021-2023 | Precision 1, Total30, Simbrinza |
| Bausch & Lomb Americas INC. | $674.85 | 2022-2025 | Miebo, Xiidra, Infuse |
| Allergan, INC. | $286.20 | 2019-2022 | |
| Optos, INC. | $259.43 | 2019-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Lkc Technologies, INC. | $251.86 | 2023-2025 | |
| Harrow Eye, LLC | $235.62 | 2024-2025 | Vevye |
| Johnson & Johnson Vision Care, INC. | $224.76 | 2020-2025 | Acuvue |
| Notal Vision, INC. | $184.35 | 2025 | Foresee Home |
| Shire North American Group INC | $172.34 | 2019 | |
| Kala Pharmaceuticals, INC. | $166.69 | 2021 | |
| Glaukos Corporation | $115.53 | 2022-2025 | Photrexa Viscous and Photrexa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare, INC. | $107.11 | 2024 | |
| Novartis Pharmaceuticals Corporation | $53.97 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $48.08 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $41.33 | 2024 | Oxervate |
| Biotissue Holdings INC. | $38.69 | 2023-2024 | |
| Thea Pharma INC. | $23.55 | 2023 | |
| Abb Con-Cise Optical Group LLC | $18.79 | 2019 | |
| Maculogix, INC. | $15.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.